Literature DB >> 15782307

Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome.

Velidi H Rao1, George E Lees, Clifford E Kashtan, Duane C Delimont, Rakesh Singh, Daniel T Meehan, Gautam Bhattacharya, Brian R Berridge, Dominic Cosgrove.   

Abstract

Matrix metalloproteinases (MMPs) play an important regulatory role in many biological and pathological processes and their specific role in Alport syndrome (AS) is not yet clearly defined. In this study, the naturally occurring canine X-linked AS was used to demonstrate a potential role for MMP-3 and MMP-7 in Alport renal pathogenesis. Recently, we demonstrated that the expression of MMP-2, MMP-9 and MMP-14 was upregulated in the renal cortex of dogs with a spontaneous form of XLAS. In the present study, we examined necropsy samples of renal cortex from normal and XLAS dogs for MMP-3 and MMP-7 as they have the potential to activate MMP-2 and MMP-9. Immunohistochemical analysis showed strong immunostaining for both MMP-3 and MMP-7 in the interstitial space of XLAS kidneys, while virtually no immunostaining was observed in similar fields from normal dogs. RT-PCR and casein zymography confirmed that both mRNA transcripts and activities of MMP-3 and MMP-7 are elevated in XLAS kidneys. The induction of these MMPs likely contributes to tissue destruction associated with the fibrogenic process, while augmenting the activation of MMP-2 and MMP-9 by MMP-3 and MMP-7 in XLAS. Thus, these data further implicate a role for the MMPs in progressive renal pathogenesis associated with AS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15782307     DOI: 10.1007/s00467-004-1805-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.

Authors:  R Kalluri; C F Shield; P Todd; B G Hudson; E G Neilson
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

2.  Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS).

Authors:  Velidi H Rao; George E Lees; Clifford E Kashtan; Ryochi Nemori; Rakesh K Singh; Daniel T Meehan; Kathyrn Rodgers; Brian R Berridge; Gautam Bhattacharya; Dominic Cosgrove
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

Review 3.  Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease.

Authors:  C Ries; P E Petrides
Journal:  Biol Chem Hoppe Seyler       Date:  1995-06

Review 4.  Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes.

Authors:  C E Kashtan
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

5.  New form of X-linked dominant hereditary nephritis in dogs.

Authors:  G E Lees; R G Helman; C E Kashtan; A F Michael; L D Homco; N J Millichamp; Z T Camacho; J W Templeton; Y Ninomiya; Y Sado; I Naito; Y Kim
Journal:  Am J Vet Res       Date:  1999-03       Impact factor: 1.156

6.  Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.

Authors:  D Cosgrove; K Rodgers; D Meehan; C Miller; K Bovard; A Gilroy; H Gardner; V Kotelianski; P Gotwals; A Amatucci; R Kalluri
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

7.  Human progelatinase A can be activated by matrilysin.

Authors:  T Crabbe; B Smith; J O'Connell; A Docherty
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

8.  Activation of TIMP-2/progelatinase A complex by stromelysin.

Authors:  K Miyazaki; F Umenishi; K Funahashi; N Koshikawa; H Yasumitsu; M Umeda
Journal:  Biochem Biophys Res Commun       Date:  1992-06-30       Impact factor: 3.575

9.  Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin.

Authors:  U I Sires; G Murphy; V M Baragi; C J Fliszar; H G Welgus; R M Senior
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

10.  Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis.

Authors:  Kathyrn D Rodgers; Velidi Rao; Daniel T Meehan; Nicole Fager; Philip Gotwals; Sarah T Ryan; Victor Koteliansky; Ryoichi Nemori; Dominic Cosgrove
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

View more
  10 in total

1.  Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome.

Authors:  Velidi H Rao; Daniel T Meehan; Duane Delimont; Motowo Nakajima; Takashi Wada; Michael Ann Gratton; Dominic Cosgrove
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Gene expression analysis in a canine model of X-linked Alport syndrome.

Authors:  Kimberly A Greer; Marnie A Higgins; Melissa L Cox; Timothy P Ryan; Brian R Berridge; Clifford E Kashtan; George E Lees; Keith E Murphy
Journal:  Mamm Genome       Date:  2006-09-08       Impact factor: 2.957

3.  Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis.

Authors:  Cory M Yamashita; Lior Dolgonos; Rachel L Zemans; Scott K Young; Jennifer Robertson; Natalie Briones; Tomoko Suzuki; Megan N Campbell; Jack Gauldie; Derek C Radisky; David W H Riches; Guoying Yu; Naftali Kaminski; Christopher A G McCulloch; Gregory P Downey
Journal:  Am J Pathol       Date:  2011-08-24       Impact factor: 4.307

Review 4.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

Review 5.  Soluble biglycan as a biomarker of inflammatory renal diseases.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Jinyang Zeng-Brouwers; Renato V Iozzo; Liliana Schaefer
Journal:  Int J Biochem Cell Biol       Date:  2014-08-01       Impact factor: 5.085

Review 6.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

7.  MMP-3 activation is involved in copper oxide nanoparticle-induced epithelial-mesenchymal transition in human lung epithelial cells.

Authors:  Yuanbao Zhang; Yiqun Mo; Jiali Yuan; Yue Zhang; Luke Mo; Qunwei Zhang
Journal:  Nanotoxicology       Date:  2022-02-02       Impact factor: 5.881

Review 8.  Matrix Metalloproteinases-7 and Kidney Fibrosis.

Authors:  Ben Ke; Chuqiao Fan; Liping Yang; Xiangdong Fang
Journal:  Front Physiol       Date:  2017-02-10       Impact factor: 4.566

Review 9.  Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis.

Authors:  Anders Tveita; Ole Petter Rekvig; Svetlana N Zykova
Journal:  Arthritis Res Ther       Date:  2008-12-01       Impact factor: 5.156

10.  Matrix metalloproteinase-2, -7, and -9 activities in dogs with idiopathic pulmonary fibrosis compared to healthy dogs and dogs with other respiratory diseases.

Authors:  Merita Määttä; Henna P Laurila; Saila Holopainen; Kaisa Aaltonen; Liisa Lilja-Maula; Sanna Viitanen; Minna M Rajamäki
Journal:  J Vet Intern Med       Date:  2020-12-04       Impact factor: 3.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.